| Active, not recruiting | 2 | 68 | US, RoW | Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta® | Effector Therapeutics, Medpace, Inc., ICON plc | Non-small Cell Lung Cancer | 10/24 | 12/24 | | |
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes |
|
|
| Active, not recruiting | 2 | 120 | US, RoW | nab-sirolimus, ABI-009 | Aadi Bioscience, Inc. | Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm | 12/24 | 12/25 | | |
